RT Journal Article
SR Electronic
T1 Relationship between the ABO Blood Group and the COVID-19 Susceptibility
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.11.20031096
DO 10.1101/2020.03.11.20031096
A1 Zhao, Jiao
A1 Yang, Yan
A1 Huang, Hanping
A1 Li, Dong
A1 Gu, Dongfeng
A1 Lu, Xiangfeng
A1 Zhang, Zheng
A1 Liu, Lei
A1 Liu, Ting
A1 Liu, Yukun
A1 He, Yunjiao
A1 Sun, Bin
A1 Wei, Meilan
A1 Yang, Guangyu
A1 Wang, Xinghuan
A1 Zhang, Li
A1 Zhou, Xiaoyang
A1 Xing, Mingzhao
A1 Wang, Peng George
YR 2020
UL http://medrxiv.org/content/early/2020/03/27/2020.03.11.20031096.abstract
AB The novel coronavirus disease-2019 (COVID-19) has been spreading around the world rapidly and declared as a pandemic by WHO. Here, we compared the ABO blood group distribution in 2,173 patients with COVID-19 confirmed by SARS-CoV-2 test from three hospitals in Wuhan and Shenzhen, China with that in normal people from the corresponding regions. The results showed that blood group A was associated with a higher risk for acquiring COVID-19 compared with non-A blood groups, whereas blood group O was associated with a lower risk for the infection compared with non-O blood groups. This is the first observation of an association between the ABO blood type and COVID-19. It should be emphasized, however, that this is an early study with limitations. It would be premature to use this study to guide clinical practice at this time, but it should encourage further investigation of the relationship between the ABO blood group and the COVID-19 susceptibility.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot ApplicableAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are included within the article.